Neurofibromatosis Treatment Market Set to Record Exponential Growth by 2023

Neurofibromatosis treatment is a genetic condition that disrupts the cell growth in your nervous system, causing formation of tumors on nerve tissue. These formed tumors may develop anywhere in the nervous system of the victim, which may include the brain, spinal cord and nerves. Neurofibromatosis is usually diagnosed in childhood or early adulthood. The tumors are noncancerous (benign) in most of the cases, but in some cases these tumors become cancerous (malignant) tumors. People suffering with neurofibromatosis often experience only mild symptom and effects may range from hearing loss, learning impairment, and heart and blood vessel (cardiovascular) complications to severe disability due to nerve compression by tumors, loss of vision and severe pain. There is no specific treatment for neurofibromatosis, but treatment aims to maximize healthy growth and development and to manage complications as soon as they arise. When neurofibromatosis causes large tumors or tumors that press on a nerve, surgery may help ease symptoms. Other therapies such as stereotactic radiosurgery, medications to control pain or physical therapy are proved to be beneficial for the affected people. There are three types of neurofibromatosis, known as neurofibromatosis type 1 (NF1), the most common one, and neurofibromatosis type 2 (NF2). One more type of neurofibromatosis which has been identified recently is known as Schwannomatosis, is a rare type and little is known about it. The factors that would drive the neurofibromatosis treatment market includes the drugs which are in the clinical trials and are anticipated to be a break through treatment for neurofibromatosis cases.

Request Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=7156

The neurofibromatosis treatment market can be segmented into drug therapy, surgery, radiation therapy and chemotherapy. Surgery is the most preferred option for the removal of the tumors. Other treatments like radiation therapy and chemotherapy are also recommended in the neurofibromatosis treatments market. In case of NF2 tumors, MRI can felicitate the early treatment of the tumors by revealing the size of the tumors. Surgery to remove tumors completely is one option but may result in hearing loss. Surgery also can correct cataracts and retinal abnormalities. There is no currently accepted medical treatment or drug for schwanomatosis, but surgical management is often effective. Pain usually subsides when tumors are removed completely. There are currently no drugs in the market for neurofibromatosis treatment, however ever certain drugs in the phase III of the clinical trials include Lamotrigine (Erasmus Medical Center), and Tamsulosin HCL (GL Pharm Tech Corporation). The drugs in the phase II of the clinical trials include Cabozantinib (University of Alabama at Birmingham), RAD001 (Assistance Publique – Hôpitaux de Paris), Gleevec (Indiana University), Everolimus (Texas Neurofibromatosis Foundation) and others.

Geographically, Neurofibromatosis is an orphan disease, and the prevalence rate of neurofibromatosis is low. According to oxford journals the prevalence rate defers from region to region. The prevalence in the U.S. is 1 in 3,000, in Eastern Europe is 1 in 15,000, in Oceania is 1 in 10,000 and in Western Europe and Middle East is 1 in 10,000.

Request For TOC : https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=7156

The organization and institutes participating in the neurofibromatosis treatment market include Erasmus Medical Center, GL Pharm Tech Corporation, University of Alabama at Birmingham, Assistance Publique – Hôpitaux de Paris, Indiana University, Texas Neurofibromatosis Foundation and others. The institutes and organization are involved in discovering of novel drug therapy for the treatment of Neurofibromatosis.

About us:

Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact us:

Transparency Market Research
90 State Street,
Suite 700,
Albany
NY – 12207
United States
Tel: +1-518-618-1030
USA – Canada Toll Free 866-552-3453
Email: [email protected]
Website: http://www.transparencymarketresearch.com/